Recombinant fibroblast growth factor-18 (sprifermin) enhances microfracture-induced cartilage healing.

ABSTRACT: Posttraumatic osteoarthritis is a disabling condition impacting the mostly young and active population. In the present study, we investigated the impact of intra-articular sprifermin, a recombinant truncated fibroblast growth factor 18, on the outcome of microfracture treatment, a widely used surgical technique to enhance cartilage healing at the site of injury. For this study, we created a cartilage defect and performed microfracture treatment in fetlock joints of 18 horses, treated joints with one of three doses of sprifermin (10, 30, or 100 μg) or with saline, hyaluronan, and evaluated animals functional and structural outcomes over 24 weeks. For primary outcome measures, we performed histological evaluations and gene expression analysis of aggrecan, collagen types I and II, and cartila

SUBMITTER: Hendesi H 

PROVIDER: S-EPMC8560655 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature